Dr. Jonathan M. Hand, M.D.
Infectious Disease (Infectious Disease Physician)
1514 Jefferson Hwy
New Orleans, LA 70121
Who else practices at this address →
Jefferson Parish includes primary care (18% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- Louisiana State University School of Medicine in New Orleans (2010)
- Years since graduation
- 16
- In the NPI registry since
- 2010
- Medicare patients seen, 2024
- 153
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2010Medical school: Louisiana State University School of Medicine in New Orleans
- 2010Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Infectious Disease Physician primary
LA license MD.207707 - Student in an Organized Health Care Education/Training Program
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Ochsner Medical Center Acute New Orleans, LA
- Ochsner Medical Center - Baton Rouge Baton Rouge, LA
Medical groups
- Ochsner Clinic LLC (2,864 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 153
- Services billed
- 272
- Patients’ average age
- 66
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 144 | 72 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 86 | 78 |
| Established patient office or other outpatient visit, 40-54 minutes | 47 | 41 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Biktarvy (bictegrav/emtricit/tenofov ala) | 114 |
| Ceftriaxone (ceftriaxone sodium) Other prescribers in New Orleans, LA | 47 |
| Ertapenem (ertapenem sodium) | 35 |
| Doxycycline Monohydrate Other prescribers in New Orleans, LA | 33 |
| Triumeq (abacavir/dolutegravir/lamivudi) | 32 |
| Cefadroxil Other prescribers in New Orleans, LA | 26 |
| Daptomycin | 24 |
| Tivicay (dolutegravir sodium) | 23 |
| Sulfamethoxazole-Trimethoprim (sulfamethoxazole/trimethoprim) Other prescribers in New Orleans, LA | 19 |
| Doxycycline Hyclate Other prescribers in New Orleans, LA | 17 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 4 companies reported 7 payments worth $1,636 in total to this clinician.
| Pfizer Inc. | $1,400 |
|---|---|
| AstraZeneca Pharmaceuticals LP | $120 |
| La Jolla Pharmaceutical Company | $92.70 |
| Amgen Inc. | $23.29 |
| Consulting Fee | $1,400 |
|---|---|
| Food and Beverage | $169 |
| Travel and Lodging | $67.30 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Pfizer Inc. Sep 19, 2025 | Consulting Fee PREVNAR 20 · VACCINES | $1,050 |
| Pfizer Inc. Sep 19, 2025 | Consulting Fee PREVNAR 20 · VACCINES | $350 |
| AstraZeneca Pharmaceuticals LP Oct 20, 2025 | Travel and Lodging travel to Atlanta, GA · in-kind Company’s descriptionResearch Related Service | $67.30 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 7 industry-funded studies in 2025, from 6 companies. The companies reported $371,129 in research payments for these studies, mostly to the institutions running them.
- A phase 4 study using a testnegative design to evaluate the effectiveness of a 20VALENT pneumococcal conjugate vaccine against vaccinetype radiologicallyconfirmed communityacquired pneumonia in adults 65 years of age
Pfizer Inc. - A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With …
Janssen Research & Development, LLC - A Study to Assess the Safety and Risk of Hypersensitivity Reactions of Sulbactam-durlobactam in Adults With Acinetobacter Baumannii-calcoaceticus (ABC) Complex Infection
La Jolla Pharmaceutical Company · Recruiting · NCT06746883 - A Phase I-III Randomized Double blind Study to Evaluate the Safety and Neutralizing Activity of AZD5156-AZD3152 for Pre exposure Prophylaxis of COVID 19 in Participants with Conditions Causing Immune Impairment
AstraZeneca UK Limited - A Phase 3, Multicenter, Prospective, Randomized, Double-blind Study of Two Treatment Regimens for Candidemia and/or Invasive Candidiasis: Intravenous Echinocandin followed by Oral Ibrexafungerp versus Intravenous Echi…
Scynexis, Inc. - A Phase III, Multicentre, Randomised, Double blind, Parallel group, Placebo controlled Study to Evaluate the Efficacy and Safety of Tozorakimab (MEDI3506) in Patients Hospitalised for Viral Lung Infection Requiring Su…
AstraZeneca Pharmaceuticals LP - A Phase 3 Randomized Open label Study to Assess the Immunogenicity and Safety of IVX A12 when Co-administered with a licensed influenza vaccine
AstraZeneca Pharmaceuticals LP
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.